EMEA (Europe, Middle East and Africa) Recombinant Protein Drugs Industry 2018 Market Research Report

Published: Dec, 2017 | Pages: 114 | Publisher: QYResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

In this report, the EMEA Recombinant Protein Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Doses), revenue (Million USD), market share and growth rate of Recombinant Protein Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Recombinant Protein Drugs market competition by top manufacturers/players, with Recombinant Protein Drugs sales volume (K Doses), price (USD/Dose), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Novo Nordisk
    Amgen
    Sanofi
    Eli Lilly
    Merck Serono
    Ortho Biotech
    Roche
    Kyowa Hakko Kirin
    Pharmingen
    Abcam
    GenSci
    SL PHARM
    Dongbao Pharm
    Ankebio
    NCPC
    Heng Rui

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Recombinant DNA
    Recombinant RNA

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Pharmaceutical Industry
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 Table of Contents

EMEA (Europe, Middle East and Africa) Recombinant Protein Drugs Market Report 2017
1 Recombinant Protein Drugs Overview
    1.1 Product Overview and Scope of Recombinant Protein Drugs
    1.2 Classification of Recombinant Protein Drugs
        1.2.1 EMEA Recombinant Protein Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Recombinant Protein Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Recombinant DNA
        1.2.4 Recombinant RNA
    1.3 EMEA Recombinant Protein Drugs Market by Application/End Users
        1.3.1 EMEA Recombinant Protein Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Pharmaceutical Industry
        1.3.3 Other
    1.4 EMEA Recombinant Protein Drugs Market by Region
        1.4.1 EMEA Recombinant Protein Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Recombinant Protein Drugs (2012-2022)
        1.5.1 EMEA Recombinant Protein Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Recombinant Protein Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Recombinant Protein Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Recombinant Protein Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Recombinant Protein Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Recombinant Protein Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Recombinant Protein Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Recombinant Protein Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Recombinant Protein Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Recombinant Protein Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Recombinant Protein Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Recombinant Protein Drugs (Volume) by Application
    2.4 EMEA Recombinant Protein Drugs (Volume and Value) by Region
        2.4.1 EMEA Recombinant Protein Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Recombinant Protein Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Recombinant Protein Drugs Sales Price by Region (2012-2017)

3 Europe Recombinant Protein Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Recombinant Protein Drugs Sales and Value (2012-2017)
        3.1.1 Europe Recombinant Protein Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Recombinant Protein Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Recombinant Protein Drugs Sales and Market Share by Type
    3.3 Europe Recombinant Protein Drugs Sales and Market Share by Application
    3.4 Europe Recombinant Protein Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Recombinant Protein Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Recombinant Protein Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Recombinant Protein Drugs Sales and Growth Rate (2012-2017)

4 Middle East Recombinant Protein Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Recombinant Protein Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Recombinant Protein Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Recombinant Protein Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Recombinant Protein Drugs Sales and Market Share by Type
    4.3 Middle East Recombinant Protein Drugs Sales and Market Share by Application
    4.4 Middle East Recombinant Protein Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Recombinant Protein Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Recombinant Protein Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Recombinant Protein Drugs Sales and Growth Rate (2012-2017)

5 Africa Recombinant Protein Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Recombinant Protein Drugs Sales and Value (2012-2017)
        5.1.1 Africa Recombinant Protein Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Recombinant Protein Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Recombinant Protein Drugs Sales and Market Share by Type
    5.3 Africa Recombinant Protein Drugs Sales and Market Share by Application
    5.4 Africa Recombinant Protein Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Recombinant Protein Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Recombinant Protein Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Recombinant Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Recombinant Protein Drugs Sales and Growth Rate (2012-2017)

6 EMEA Recombinant Protein Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Novo Nordisk
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Amgen
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Amgen Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Sanofi
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Sanofi Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Eli Lilly
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Eli Lilly Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merck Serono
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merck Serono Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Ortho Biotech
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Roche
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Roche Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Kyowa Hakko Kirin
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Pharmingen
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Pharmingen Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Abcam
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Recombinant Protein Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Abcam Recombinant Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 GenSci
    6.12 SL PHARM
    6.13 Dongbao Pharm
    6.14 Ankebio
    6.15 NCPC
    6.16 Heng Rui

7 Recombinant Protein Drugs Manufacturing Cost Analysis
    7.1 Recombinant Protein Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Recombinant Protein Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Recombinant Protein Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Recombinant Protein Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Recombinant Protein Drugs Market Forecast (2017-2022)
    11.1 EMEA Recombinant Protein Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Recombinant Protein Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Recombinant Protein Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Recombinant Protein Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Recombinant Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Recombinant Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Recombinant Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Recombinant Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Recombinant Protein Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Recombinant Protein Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer

List of Tables and Figures

    Figure Product Picture of Recombinant Protein Drugs
    Figure EMEA Recombinant Protein Drugs Sales Volume (K Doses) by Type (2012-2022)
    Figure EMEA Recombinant Protein Drugs Sales Volume Market Share by Type (Product Category) in 2016
    Figure Recombinant DNA Product Picture
    Figure Recombinant RNA Product Picture
    Figure EMEA Recombinant Protein Drugs Sales Volume (K Doses) by Application (2012-2022)
    Figure EMEA Sales Market Share of Recombinant Protein Drugs by Application in 2016
    Figure Pharmaceutical Industry Examples
    Table Key Downstream Customer in Pharmaceutical Industry
    Figure Other Examples
    Table Key Downstream Customer in Other
    Figure EMEA Recombinant Protein Drugs Market Size (Million USD) by Region (2012-2022)
    Figure Europe Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Europe Recombinant Protein Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure Middle East Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Middle East Recombinant Protein Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure Africa Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Africa Recombinant Protein Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure EMEA Recombinant Protein Drugs Sales Volume and Growth Rate (2012-2022)
    Figure EMEA Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure EMEA Recombinant Protein Drugs Market Major Players Product Sales Volume (K Doses) (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales Volume (K Doses) of Major Players (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales Share by Players (2012-2017)
    Figure 2016 Recombinant Protein Drugs Sales Share by Players
    Figure 2017 Recombinant Protein Drugs Sales Share by Players
    Figure EMEA Recombinant Protein Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
    Table EMEA Recombinant Protein Drugs Revenue (Million USD) by Players (2012-2017)
    Table EMEA Recombinant Protein Drugs Revenue Share by Players (2012-2017)
    Table 2016 EMEA Recombinant Protein Drugs Revenue Share by Players
    Table 2017 EMEA Recombinant Protein Drugs Revenue Share by Players
    Table EMEA Recombinant Protein Drugs Sale Price (USD/Dose) by Players (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales (K Doses) and Market Share by Type (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales Share by Type (2012-2017)
    Figure Sales Market Share of Recombinant Protein Drugs by Type (2012-2017)
    Figure EMEA Recombinant Protein Drugs Sales Market Share by Type (2012-2017)
    Table EMEA Recombinant Protein Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
    Table EMEA Recombinant Protein Drugs Revenue Share by Type (2012-2017)
    Figure Revenue Market Share of Recombinant Protein Drugs by Type in 2016
    Table EMEA Recombinant Protein Drugs Sale Price (USD/Dose) by Type (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales (K Doses) and Market Share by Application (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales Share by Application (2012-2017)
    Figure Sales Market Share of Recombinant Protein Drugs by Application (2012-2017)
    Figure EMEA Recombinant Protein Drugs Sales Market Share by Application in 2016
    Table EMEA Recombinant Protein Drugs Sales (K Doses) and Market Share by Region (2012-2017)
    Table EMEA Recombinant Protein Drugs Sales Share by Region (2012-2017)
    Figure Sales Market Share of Recombinant Protein Drugs by Region (2012-2017)
    Figure EMEA Recombinant Protein Drugs Sales Market Share in 2016
    Table EMEA Recombinant Protein Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
    Table EMEA Recombinant Protein Drugs Revenue Share by Region (2012-2017)
    Figure Revenue Market Share of Recombinant Protein Drugs by Region (2012-2017)
    Figure EMEA Recombinant Protein Drugs Revenue Market Share Regions in 2016
    Table EMEA Recombinant Protein Drugs Sales Price (USD/Dose) by Region (2012-2017)
    Figure Europe Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Europe Recombinant Protein Drugs Revenue and Growth Rate (2012-2017)
    Table Europe Recombinant Protein Drugs Sales (K Doses) by Type (2012-2017)
    Table Europe Recombinant Protein Drugs Market Share by Type (2012-2017)
    Figure Europe Recombinant Protein Drugs Market Share by Type in 2016
    Table Europe Recombinant Protein Drugs Sales (K Doses) by Application (2012-2017)
    Table Europe Recombinant Protein Drugs Market Share by Application (2012-2017)
    Figure Europe Recombinant Protein Drugs Market Share by Application in 2016
    Table Europe Recombinant Protein Drugs Sales (K Doses) by Countries (2012-2017)
    Table Europe Recombinant Protein Drugs Sales Market Share by Countries (2012-2017)
    Figure Europe Recombinant Protein Drugs Sales Market Share by Countries (2012-2017)
    Figure Europe Recombinant Protein Drugs Sales Market Share by Countries in 2016
    Table Europe Recombinant Protein Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Europe Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Europe Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Europe Recombinant Protein Drugs Revenue Market Share by Countries in 2016
    Figure Germany Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure France Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure UK Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Russia Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Italy Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Benelux Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Middle East Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Middle East Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2017)
    Table Middle East Recombinant Protein Drugs Sales (K Doses) by Type (2012-2017)
    Table Middle East Recombinant Protein Drugs Market Share by Type (2012-2017)
    Figure Middle East Recombinant Protein Drugs Market Share by Type (2012-2017)
    Table Middle East Recombinant Protein Drugs Sales (K Doses) by Applications (2012-2017)
    Table Middle East Recombinant Protein Drugs Market Share by Applications (2012-2017)
    Figure Middle East Recombinant Protein Drugs Sales Market Share by Application in 2016
    Table Middle East Recombinant Protein Drugs Sales Volume (K Doses) by Countries (2012-2017)
    Table Middle East Recombinant Protein Drugs Sales Volume Market Share by Countries (2012-2017)
    Figure Middle East Recombinant Protein Drugs Sales Volume Market Share by Countries in 2016
    Table Middle East Recombinant Protein Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Middle East Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Middle East Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Middle East Recombinant Protein Drugs Revenue Market Share by Countries in 2016
    Figure Saudi Arabia Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Israel Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure UAE Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Iran Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Africa Recombinant Protein Drugs Revenue (Million USD) and Growth Rate (2012-2017)
    Table Africa Recombinant Protein Drugs Sales (K Doses) by Type (2012-2017)
    Table Africa Recombinant Protein Drugs Sales Market Share by Type (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales Market Share by Type (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales Market Share by Type in 2016
    Table Africa Recombinant Protein Drugs Sales (K Doses) by Application (2012-2017)
    Table Africa Recombinant Protein Drugs Sales Market Share by Application (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales Market Share by Application (2012-2017)
    Table Africa Recombinant Protein Drugs Sales Volume (K Doses) by Countries (2012-2017)
    Table Africa Recombinant Protein Drugs Sales Market Share by Countries (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales Market Share by Countries (2012-2017)
    Figure Africa Recombinant Protein Drugs Sales Market Share by Countries in 2016
    Table Africa Recombinant Protein Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Africa Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Africa Recombinant Protein Drugs Revenue Market Share by Countries (2012-2017)
    Figure Africa Recombinant Protein Drugs Revenue Market Share by Countries in 2016
    Figure South Africa Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Nigeria Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Egypt Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Algeria Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Table Novo Nordisk Recombinant Protein Drugs Basic Information List
    Table Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Novo Nordisk Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Novo Nordisk Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Novo Nordisk Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Amgen Recombinant Protein Drugs Basic Information List
    Table Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Amgen Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Amgen Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Amgen Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Sanofi Recombinant Protein Drugs Basic Information List
    Table Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Sanofi Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Sanofi Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Sanofi Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Eli Lilly Recombinant Protein Drugs Basic Information List
    Table Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Eli Lilly Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Eli Lilly Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Eli Lilly Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Merck Serono Recombinant Protein Drugs Basic Information List
    Table Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Merck Serono Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Merck Serono Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Merck Serono Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Ortho Biotech Recombinant Protein Drugs Basic Information List
    Table Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Ortho Biotech Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Ortho Biotech Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Ortho Biotech Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Roche Recombinant Protein Drugs Basic Information List
    Table Roche Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Roche Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Roche Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Roche Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Kyowa Hakko Kirin Recombinant Protein Drugs Basic Information List
    Table Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Kyowa Hakko Kirin Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Kyowa Hakko Kirin Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Pharmingen Recombinant Protein Drugs Basic Information List
    Table Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Pharmingen Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Pharmingen Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Pharmingen Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table Abcam Recombinant Protein Drugs Basic Information List
    Table Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
    Figure Abcam Recombinant Protein Drugs Sales (K Doses) and Growth Rate (2012-2017)
    Figure Abcam Recombinant Protein Drugs Sales Market Share in EMEA (2012-2017)
    Figure Abcam Recombinant Protein Drugs Revenue Market Share in EMEA (2012-2017)
    Table GenSci Recombinant Protein Drugs Basic Information List
    Table SL PHARM Recombinant Protein Drugs Basic Information List
    Table Dongbao Pharm Recombinant Protein Drugs Basic Information List
    Table Ankebio Recombinant Protein Drugs Basic Information List
    Table NCPC Recombinant Protein Drugs Basic Information List
    Table Heng Rui Recombinant Protein Drugs Basic Information List
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of Recombinant Protein Drugs
    Figure Manufacturing Process Analysis of Recombinant Protein Drugs
    Figure Recombinant Protein Drugs Industrial Chain Analysis
    Table Raw Materials Sources of Recombinant Protein Drugs Major Manufacturers in 2016
    Table Major Buyers of Recombinant Protein Drugs
    Table Distributors/Traders List
    Figure EMEA Recombinant Protein Drugs Sales (K Doses) and Growth Rate Forecast (2017-2022)
    Figure EMEA Recombinant Protein Drugs Revenue and Growth Rate Forecast (2017-2022)
    Figure EMEA Recombinant Protein Drugs Price (USD/Dose) and Trend Forecast (2017-2022)
    Table EMEA Recombinant Protein Drugs Sales (K Doses) Forecast by Region (2017-2022)
    Figure EMEA Recombinant Protein Drugs Sales Market Share Forecast by Region (2017-2022)
    Table EMEA Recombinant Protein Drugs Revenue (Million USD) Forecast by Region (2017-2022)
    Figure EMEA Recombinant Protein Drugs Revenue Market Share Forecast by Region (2017-2022)
    Table Europe Recombinant Protein Drugs Sales (K Doses) Forecast by Countries (2017-2022)
    Figure Europe Recombinant Protein Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Europe Recombinant Protein Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Europe Recombinant Protein Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table Middle East Recombinant Protein Drugs Sales (K Doses) Forecast by Countries (2017-2022)
    Figure Middle East Recombinant Protein Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Middle East Recombinant Protein Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Middle East Recombinant Protein Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table Africa Recombinant Protein Drugs Sales (K Doses) Forecast by Countries (2017-2022)
    Figure Africa Recombinant Protein Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Africa Recombinant Protein Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Africa Recombinant Protein Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table EMEA Recombinant Protein Drugs Sales (K Doses) Forecast by Type (2017-2022)
    Figure EMEA Recombinant Protein Drugs Sales Market Share Forecast by Type (2017-2022)
    Table EMEA Recombinant Protein Drugs Sales (K Doses) Forecast by Application (2017-2022)
    Figure EMEA Recombinant Protein Drugs Sales Market Share Forecast by Application (2017-2022)
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources

To request a free sample copy of this report, please complete the form below.

Interested in this report? Get your FREE sample now! Get a Free Sample

Did you know?

Our library has over 100000 reports on 1000s of topics

Over 100+ Fortune 500 companies rely on us

90,000+ people come to us for insights every month

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.